From Palliative Care to a Second Chance: A Pakistani DLBCL Patient's CAR-T Journey in China
- Troy Chen
- Jun 25
- 7 min read
The story of Muhammad ZAKRIA — a 36-year-old hospital worker from Quetta, Pakistan, who was told there were no more options at home, then found a way forward in Shanghai.
A Diagnosis That Changed Everything
For 36-year-old Muhammad ZAKRIA, the word "healthy" had become a distant memory long before we ever spoke to him. Muhammad works as a support staff member at a public hospital in Quetta, the capital of Pakistan's southwestern Balochistan province — a city often called the "Fruit Garden" for its orchards.
In 2021, his life changed with a single diagnosis: Diffuse Large B-Cell Lymphoma (DLBCL), an aggressive form of blood cancer. The years that followed were a punishing cycle of chemotherapy rounds and pain that few of us could imagine enduring.
In 2024, Muhammad underwent a bone marrow transplant at Aga Khan University Hospital in Pakistan. He placed every hope in that surgery, believing he could slowly return to an ordinary life afterward.
But the cancer came back just 20 days later.
For Muhammad and his family, that was more than a medical setback — it was the collapse of hope. Back home, his doctors could offer only one path: palliative care. No cure. Just medication to ease the pain.
His primary physician told him directly:
"We have done everything we can. You'll need to seek treatment abroad. We can write the referral letter, but you'll have to find a hospital yourself."
That was the moment Muhammad and his family began searching the world for an answer.
Part 1 — A Faint Light: Choosing Shanghai
After receiving the necessary approvals from Pakistan's National Medical Council, Muhammad began reaching out to hospitals across the globe. His emails traveled to Germany, Singapore, Austria, India, the United States, and Australia — each one a small SOS bottle cast into the unknown, with no guarantee of when — or how — it would be answered.
- Germany replied slowly.
- Singapore and India sent back plans that felt unclear.
- One hospital replied quickly, with a clear communication style and a thoughtful initial treatment proposal:
Shanghai Jiahui International Hospital.
Muhammad made his decision faster than he expected. Early in 2026, he and his family boarded a flight to Shanghai — exhausted, in pain, but still holding on to a single thread of hope.
Part 2 — CAR-T Therapy at Jiahui International Cancer Center
Once admitted, the scans confirmed the severity of Muhammad's condition. He was diagnosed with Stage 4B lymphoma, with cancer spread to his lungs, pleura, and bones. Because the disease had relapsed only 20 days after transplant, it was officially classified as "relapsed/refractory" — meaning standard treatment was no longer effective.
A large tumor mass was pressing on his lungs and bones. The pain kept him awake at night; only high-dose painkillers and multiple strong sedatives could offer brief relief. He also suffered from persistent high fever, night sweats, and rapid weight loss.
Why China — and Why Now?
Muhammad had, by fortunate timing, come to a country that is currently leading the world in CAR-T cell therapy.
- According to a recent article in **Frontiers in Pharmacology**, China has been at the forefront of CAR-T research since 2016. As of October 2025, **China ranks #1 globally in the number of CAR-T clinical trials**.
- A separate study notes that since 2021, **four domestically developed CAR-T products have been approved in China** for the treatment of lymphoma and multiple myeloma, with efficacy reaching global standards.
In short: when conventional medicine says "nothing more can be done," China often still has a next step.
The Treatment Plan
In early April, Muhammad began his multi-week CAR-T journey at Jiahui International Cancer Center, led by Dr. HAO Siguo (郝思国), Chief Hematology Specialist, and Dr. DONG Yan (董艳) as his primary attending physician.
The process followed the standard CAR-T sequence:
1. T-cell collection — Muhammad's own T cells were harvested.
2. Bridging therapy — Given the heavy tumor burden, Dr. Hao designed a personalized regimen combining chemotherapy + localized radiotherapy to shrink the tumor before reinfusion, controlling reinfusion-related risks.
3. Lymphodepleting chemotherapy — to prepare the body for the modified cells.
4. CAR-T cell reinfusion.
By early May, the first PET-CT scans delivered encouraging results:
- Lymph node lesions had visibly shrunk.
- Tumor marker LDH (lactate dehydrogenase) had returned to normal.
- The pain that had previously required high-dose sedatives was now manageable with just 2–3 low-dose pain pills every 12 hours — and he no longer experienced "breakthrough pain."
In the dedicated CAR-T isolation room, Muhammad said the words his medical team had been waiting for:
"I have confidence!"
With his visa nearing expiration, the oncology team prepared a one-year follow-up plan and medication guide so that Muhammad could safely continue his recovery and monitoring back in Pakistan.
Part 3 — Care That Crosses Languages and Cultures
For international patients, the medical procedure is only half the challenge. The other half is being understood.
The Language Barrier
Muhammad's mother tongue is Urdu, a language with a small global footprint. English is his bridge to the outside world, but he doesn't speak it fluently — and the medical terminology involved in CAR-T therapy is dense, even for native English speakers.
"Communication was the hardest part. Often we would finish explaining something, and he looked completely lost. The information gap was huge."
— Dr. DONG Yan, reflecting on the case
The Jiahui team refused to let language become a barrier to treatment. They:
- Used translation software to convert every important phrase into Urdu.
- Fell back on gestures, eye contact, and patient repetition when the translator fell short.
- Wrote out every key instruction, treatment plan, and precaution in plain text, so Muhammad could re-translate them at his own pace.
The Dietary Barrier
When it came to food, however, half-understanding wasn't an option. Muhammad's religious faith required halal preparation, and he specifically asked for dry-cooked dishes with the best possible flavor and presentation.
The hospital's catering team prepared customized halal meals for him — and Muhammad rewarded them by eating well throughout his stay, including six eggs a day, which his doctors credited as a meaningful boost to his recovery.
The Emotional Side
Muhammad's youngest daughter became his anchor. Her voice on video calls — and one meal of a burger together during her visit — gave him the kind of motivation no medicine can manufacture. The medical team noticed the change in his demeanor immediately, and quietly made sure family video time was uninterrupted.
Part 4 — What He Carries Home
On May 8, Muhammad boarded his flight home.
The journey was never easy. But what he brings back is more than just a stabilized scan and a one-year medication plan. It is the accumulation of every small kindness along the way:
- A smile from a nurse who knew his name.
- A halal meal prepared with care.
- The patience of a doctor who translated the same phrase three different ways until he understood.
- The body language that worked even when words didn't.
"When I get home, I will follow the follow-up plan the Jiahui doctors gave me. When I'm fully recovered, I'll go back to work.
Why This Story Matters for Patients Considering CAR-T Abroad
Muhammad's case is not unique. Every year, hundreds of patients from Pakistan, the Middle East, Central Asia, and Africa reach out to MedTourChina with the same story: "Our doctors say there's nothing more they can do." Often, that is not the final answer.
If you or a family member is facing a similar situation — relapsed or refractory lymphoma, multiple myeloma, or another hematological malignancy — and CAR-T therapy is being discussed, here are a few things to know:
Concern | What You Should Know
Is CAR-T available for international patients? | Yes — multiple Chinese hospitals accept international patients with proper medical visas and pre-screening.
How long do I need to stay in China? | Typically 4–8 weeks for collection, bridging therapy, reinfusion, and initial monitoring.
What about language? | Most top Chinese hospitals have dedicated international patient departments with English-speaking coordinators. MedTourChina can also arrange a personal translator for the entire stay.
Can I continue treatment at home? | Yes. We coordinate with your home oncologist and provide full translated medical records + a one-year follow-up plan.
What about cost? | Significantly lower than US/Europe, with no waiting lists. Contact us for a personalized quote.
How MedTourChina Can Help
We work with patients and families across Pakistan, Bangladesh, the Middle East, Central Asia, Africa, and Southeast Asia to access advanced cancer treatment in China. Our services include:
- Hospital & specialist matching — We review your case and connect you with the right hematology / oncology center.
- Medical visa & documentation — We guide you through the medical visa process and prepare all required letters.
- Travel & logistics — Airport pickup, hotel near the hospital, family accommodation.
- Dedicated translation — A personal translator who stays with you for the entire medical journey.
- Dietary & cultural support — Halal, vegetarian, or other religious / cultural meal arrangements.
- Post-treatment follow-up — Translated medical records, telemedicine consults, and medication logistics for your return home.
References
1. Wang M, et al. Global panoramic analysis of clinical research in cell therapy: clinical trial landscape, marketed products, and regulatory trends. Frontiers in Pharmacology**, vol. 17, 2026.
2. Yan, L., et al. CAR-T cell therapy in China: innovations, challenges, and strategic pathways. Discover Oncology 16, 1593, 2025.
Disclaimer
The medical events described in this article are real. All descriptions of the diagnosis, treatment process, and outcomes are based on the original medical records and the objective accounts of the attending physicians and care team. The patient and his family are identified by their real names with their full informed written consent, granted prior to publication, including permission to use direct quotes and photographs.
About MedTourChina
MedTourChina is a medical tourism service that helps international patients access advanced treatment in China's leading hospitals. We work with JCI-accredited and top-tier Class 3A hospitals in Shanghai, Beijing, and beyond.
- Website: medtourchina.net
- Email: info@medtourchina.net
- WhatsApp / WeChat:+86 17742026990
Don't give up at the first "no." A second opinion — and a second chance — may be one conversation away.
Comments